Medical Oncologist, Royal Brisbane and Women's Hospital, IMDC Fellow (2019-2021)
Brisbane, Queensland
Joined September 2016
- Tweets288
- Following277
- Followers202
- Likes1.6K
Chun Loo Gan retweeted
Navigating DOAC dosing around surgeries?
@JAMA_current @OncoAlert #Anticoagulation #surgery #oncology
doi:10.1001/jama.2024.12708
Chun Loo Gan retweeted
HER2: a remarkable story of precision oncology.
Check this wonderful Nature review on targeting HER2 beyond breast.
👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing!
nature.com/articles/s41571-0…
Chun Loo Gan retweeted
The one and only @tompowles1 presenting data from the #KeyNote361 trial
🚨#ctDNA reductions were associated with improved ORR, PFS (P< 0.001), and OS (P< 0.01) in pts with previously untreated advanced UC on chemo
🚨 Changes with #pembro were more associated with long-term outcomes and were enriched with higher tTMB and PD-L1 levels!
@ASCO #ASCO24 @OncoAlert
Chun Loo Gan retweeted
Come see our #IMDC fellow @Martinzarba Saturday 8am Room S100bc present on the Favorable risk and VERY favorable risk metastatic #kidneycancer population for potential guidance on therapy selection. #IMDConline @DrChoueiri @montypal @tompowles1 @ravikanesvaran @OncoAlert #ASCO24
Chun Loo Gan retweeted
TROPICS-4 (sacituzumab govitecan vs chemo) in heavily pretreated bladder cancer missed OS. Many drugs have failed in this space (personal experience +++). Managing toxicity is important. Earlier treatment & combinations may yield different results #ASCO24 gilead.com/news-and-press/pr…
Chun Loo Gan retweeted
1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC.
nejm.org/doi/full/10.1056/NE…
Chun Loo Gan retweeted
ENZA-P in @TheLancetOncol
Lu-177 PSMA-617 + enzalutamide vs. enza alone:
● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects
Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team #ArtNet
authors.elsevier.com/c/1iw3e…
Thanks @MovemberAUS @Novartis for funding
Chun Loo Gan retweeted
Pleased to share our latest work published in @UrolOncol focusing on precision medicine in #ProstateCancer
Link 👇
authors.elsevier.com/c/1iwC7…
@anis_a_hamid @ChrisSweens1
@PeterMacRes
Chun Loo Gan retweeted
New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24
Chun Loo Gan retweeted
So proud to see the diffusion of our review on ADC toxicities, with already 25k accesses and >300 Altmetric! The article will be made free to access and download in the days surrounding #AACR24, starting today: download a copy if you have interest in ADCs! nature.com/articles/s41571-0…
Chun Loo Gan retweeted
New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !!
jnm.snmjournals.org/content/…
@DebiopharmNews @DrBenTran
@JournalofNucMed @PeterMacRes
Chun Loo Gan retweeted
Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24. Has anything changed for you based on these data?
Chun Loo Gan retweeted
#GU24 @ASCO RCC highlights:
1⃣The phase 3 KEYNOTE-564 @DrChoueiri
This landmark study demonstrated a significant improvement in overall survival compared to placebo, marking it as the first to show such a meaningful survival benefit with adjuvant therapy in RCC!
2⃣The CheckMate 67T (Saby George, MD) compared subcutaneous and intravenous nivolumab in mRCC. Results indicated non-inferiority in pharmacokinetics and efficacy for the subcutaneous method, offering a quicker, more efficient treatment option with a consistent safety profile. This development could significantly enhance patient experience and healthcare efficiency.
3⃣Patient-Centered HRQOL @crisbergerot three-phase study focused on developing a patient-centered HRQOL measure for mRCC. This innovative approach, involving patient engagement, expert input, and advocacy, aims to tailor HRQOL assessment to the specific needs of mRCC patients, promising more relevant and effective care strategies.
4⃣The CheckMate 914 trial @motzermd explored adjuvant nivolumab monotherapy versus placebo for patients with high-risk localized RCC post-nephrectomy. Unfortunately, the trial did not meet its primary endpoint of disease-free survival improvement.
@OncoAlert @urotoday @yekeduz_emre @AmandaNizamMD @TiansterZhang @cdanicas @FabioSchutz78 @OncBrothers @NazliDizman @IMG_Oncologists @kidneycan @KidneyCancer @OncLive @uromigos @BraunMDPhD
Chun Loo Gan retweeted
Delighted to announce that our new paper has been published @EUplatinum! Brain mets were found in 389/4799 (8.1%) mRCC pts and intensive systemic/focal therapies were associated with better prognosis. Special thanks to @DrChoueiri @DrDanielHeng and other collaborators @IMDConline
Chun Loo Gan retweeted
Day 3 #GU24 @ASCO Highlights #CommunityOncology
1. #KN564: Adj Pembro w/ +ve OS
2. #LITESPARK005
3. #Updates in RCC:
- CM214
- CM9ER
- CLEAR
- SubC Nivo
#OncEd #MedEd #OncTwitter #MedTwitter #gusm #kidneycancer #ThatsaWrap
1/4
Chun Loo Gan retweeted
Proud of @IMDConline posters by @ReneeSaliby #connorwells #mehulgupta who all won ASCO merit awards! 1145 IPI/nivo patient outcomes, treatment free survival and intermediate endpoints. Check it out! #awesomefellows @oncoalert @ASCO @UCalgaryMed #GU24 @DrChoueiri @DanaFarber_GU
Chun Loo Gan retweeted
Day 1 #GU24 @ASCO Highlights #CommunityOncology
1. #CONTAC02: Atezo/Cabo mCRPC
2. #BRCAAWAY: PARPi in mCRPC
3. #EMBARK: High Risk biochemical recurrence #ProstateCancer cancer
#OncEd #MedEd #OncTwitter #MedTwitter #gusm
1/4
Chun Loo Gan retweeted
Enfortumab Vedotin + pembro shows broad spectrum of activity for RR PFS and OS in all subgroups. This includes subsets such as lymph node disease, liver mets, PD-L1 status, upper tract disease, platinum eligibility. This +ve data underlines EVP as a new standard of care #GU24
Chun Loo Gan retweeted
Adjuvant pembro ⬆️ DFS (0.69) but ❌ OS (0.98) in UC, ~10% tox ++. Atezo also had ❌ OS. Nivo had 0.7 DFS but no OS data after ++ years-assuming it’s +ve seems unwise. Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO #GU24
